Korean biopharma looks for the perfect IPO formula

Expect a slew of biopharmaceutical IPOs from Korea, as companies capitalise on Seoul’s ambition to develop a biotechnology hub. That's if politics doesn't get in the way.

Korean biopharma looks for the perfect IPO formula

A clutch of South Korean biopharmaceutical companies plan to go public this year, raising capital to expand production capacity as the country strives to become a global powerhouse for the manufacture of biopharmaceutical products.

The batch of newcomers could reshape the pharmaceuticals sector they are bigger than most existing listed players and will potentially add liquidity and attract more foreign investment to one of the hottest sectors in the Korean market.


FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Print Edition

FinanceAsia Print Edition